Introduction {#sec1-1}
============

The ocular motor nerves (cranial nerves III, IV, and VI) innervate different extraocular muscles. Damage to these nerves results in complex clinical symptoms and signs, and it is difficult to rate the severity of damage. At present, the severity of damage to these nerves is usually demonstrated by describing a single symptom. For example, the Hirischberg cover-uncover test with prim bars (Rucker et al., 2011) and the Maddox rod and red glass test are used to detect ocular deviation (Newman-Toker and Rizzo, 2010). The Hess screen test and Lancaster screen test are used to test diplopia (Christoff and Guyton, 2006; Roper-Hall, 2006). Scott and Kraft (1985) developed a grading method to describe eye movement limitations. However, there is no system or scale to synthetically evaluate the severity of ocular motor nerve palsy (OMNP). To address the urgent need for a useful clinical tool, this study designed a scale based on the symptoms and signs of OMNP. The Ocular Motor Nerve Palsy Scale (OMNPS) evaluates severity by assessing diplopia at 1 meter, eye movement, palpebral fissure, pupil size, and light reflex. The reliability and validity of the scale were investigated to verify its practicability and feasibility.

Participants and Methods {#sec1-2}
========================

Participants {#sec2-1}
------------

One hundred and six patients with unilateral OMNP were enrolled through advertisement and clinical practice at the First Affiliated Hospital of Harbin Medical University, Department of Ocular Motility Disorder Treatment & Rehabilitation Center, China, from March 2016 to February 2017.

### Inclusion criteria {#sec3-1}

Patients presenting with all of the following criteria were considered for inclusion in the study: voluntary participation in the evaluation and diagnosis of unilateral isolated CN-III IV VI paralysis, a binocular visual acuity difference of less than 0.1, and able to complete a computerized diplopia test independently.

### Exclusion criteria {#sec3-2}

Patients with one or more of the following conditions were excluded from the study: color blindness, color weakness, abnormal retinal correspondence, or any other severe condition.

All patients gave signed informed consent, and the study was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University of China (approval number: 201452).

Scale design {#sec2-2}
------------

### Item selection {#sec3-3}

The five main items, diplopia at 1 meter, eye movement condition, palpebral fissure, pupil size, and light reflex, were assessed according to the clinical symptoms and signs of OMNP (Danchaivijitr, 2004; Brazis, 2009; Prasad and Volpe, 2010; Galtrey et al., 2015). The scale is displayed in **[Table 1](#T1){ref-type="table"}**.
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### Testing methods {#sec3-4}

Diplopia at 1 meter (Zhou et al., 2016, 2017): After head fixation, patients completed a computerized diplopia test at 1 meter wearing red and blue glasses. The direction and maximum angle of deviation of diplopia were measured and recorded automatically by the computer.

Eye movement (Corbett, 2003): After head fixation, patients were asked to move the eyeball toward the left and right, and straight up and down. The functional eye movement in four directions was observed and graded according to the scoring criteria.

The palpebral fissure: The frontal muscle above the eyebrow was fixed and did not affect the activity of the upper eyelid. Patients were asked to open their eyelids as wide as possible. The distance between the midpoint of the upper and lower eyelids (accurate to the millimeter) was measured.

Pupil size (Jacobson, 1998): Pupil diameter was measured using a ruler under stationary indoor lights and all testing rooms had the same level of light.

Light reflex (Cornblath, 2014): The physician directly tested the patient\'s light reflex with a flash light.

### OMNPS scoring criteria {#sec3-5}

The scale is divided into three sub-scales that reflect the type of cranial nerve damage. PART CN-IV is designed for trochlear nerve paralysis patients, and includes diplopia at 1 meter only. PART CN-VI is designed for abducens nerve paralysis, and includes diplopia at 1 meter and eye movement. PART CN-III is designed for oculomotor nerve paralysis patients and includes all five items. (1) Diplopia at 1 meter: the maximum angle of diplopia is graded on five levels, with each level representing 5°. If the maximum deviation angle is horizontal, it only needs grading; if it is vertical, the angle is multiplied by 3 before grading. (2) Eye movement: This test consists of two parts. Horizontal movement is assessed on five levels with reference to the midline and two quarter lines. Vertical movement is assessed on four levels with reference to the line of the inner and temporal canthus. (3--4) Palpebral fissure and pupil size: affected eyes are compared with healthy eyes and there are four levels for palpebral fissure and four levels for pupil size. (5) Light reflex: The direct light reflex and grading are observed. Higher scores represent more severe symptoms. The details of the scoring criteria are listed in **[Table 1](#T1){ref-type="table"}**.

### OMNPS grading by six experts {#sec3-6}

Our scale was sent to six experts by email. The experts were invited to grade the scale in relation to OMNP. The scale is shown in **[Table 2](#T2){ref-type="table"}**. The experts were asked to choose 1 (not relevant) to 4 (highly relevant) according to the item\'s relevance to OMNP. Content validity indices were calculated from the experts' scores, including item-level content validity index (I-CVI = number of experts who gave a grade of 3 or 4/number of experts), scale-level content validity index/universal agreement (S-CVI/UA = number of items graded as 3 or 4/number of items), and S-CVI/Ave = average I-CVI scores of five items.
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Content validity grading form

![](NRR-13-1851-g003)

Clinical examination procedure {#sec2-3}
------------------------------

### Physicians {#sec3-7}

The physicians familiarized themselves with the scale before administering the tests. In a pilot study, the physicians administered the test to five patients (not including the 106 patients recruited for this study) until they could run the test smoothly and accurately. The physicians were blind to the patients' medical histories. The patients received the examination in random order.

### Testing process {#sec3-8}

Three physicians tested the 106 consecutive patients. The computerized diplopia test was performed under the physicians' instruction, and data were automatically generated by computer and then graded by the physicians. To prevent bias, we applied the following procedures. The testing procedure was performed in three independent clinical consulting rooms. Communication between physicians was forbidden during the process, and the results were compared by physicians who were not involved with the research. One of the three physicians measured the patients again after 24 hours without any intervention. The data were independently cross-checked by the other two researchers.

Statistical analysis {#sec2-4}
--------------------

All normally distributed data are expressed as the mean ± SD. The data were analyzed using Statistical 19.0 software (IBM SPSS Statistics, IBM Co., Somers, NY, USA). The CVI was used to assess content validity. Factor analysis was utilized to evaluate the construct validity of PART CN-III. The intraclass correlation coefficient (ICC) with a 95% confidence interval was calculated to assess the inter-rater reliability and test-retest reliability. After comparison of the total score, the scores for each item were compared except for diplopia at 1 meter. Cronbach\'s Alpha was used to evaluate internal consistency.

Results {#sec1-3}
=======

General information {#sec2-5}
-------------------

The 106 patients with OMNP consisted of 67 males and 39 females ranging in age from 11--79 (54.72 ± 14.42) years. **[Table 3](#T3){ref-type="table"}** presents patients' scores grouped according to the affected cranial nerve.

###### 

Ocular motor nerve palsy score in 106 patients
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Validity analysis {#sec2-6}
-----------------

### Content validity {#sec3-9}

As displayed in **[Table 4](#T4){ref-type="table"}**, the I-CVI was 0.83--1, demonstrating that the five items were strongly correlated with OMNP (Pc = 0.016, K^\*^ = 0.82--1) (Polit et al., 2007). The S-CVI/UA was 0.8 (\> 0.8 indicates good content validity; Davis, 1992). S-CVI/Ave was 0.966 (\> 0.9 indicates good content validity; Waltz et al., 2005). The results indicate that the content validity of the OMNPS is good.
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Results of content validity
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### Construct validity {#sec3-10}

First, the Kaiser-Meyer-Olkin test and Bartlett\'s spherical test were performed. The Kaiser-Meyer-Olkin value was 0.792 and Bartlett\'s spherical test was significant at *P* \< 0.01, confirming that the data were suitable for factor analysis. Principal component analysis was performed. Two common factors were extracted and the contribution rate was 85.2%. After matrix rotation, eye movement condition, palpebral fissure, pupil size, and light reflex loaded on factor 1 with values of 0.867, 0.887, 0.927, and 0.899, respectively. Maximum angle of diplopia at 1 meter loaded on factor 2 with a value of 0.990. The variance, contribution rate, and cumulative contribution rate are listed in **[Table 5](#T5){ref-type="table"}**. Two common factors were extracted, demonstrating that all five items reflected symptoms and signs of OMNP. This was in agreement with the theoretical design of the scale. All of the items loaded above 0.8 on their own factor. These results show that the OMNPS PART CN-III has good construct validity.

###### 

Results of construct validity (variance, cumulative contribution rate and load values of main components)

![](NRR-13-1851-g006)

Reliability analysis {#sec2-7}
--------------------

The results of the reliability analysis are shown in **[Table 6](#T6){ref-type="table"}**. In terms of the test-retest reliability, the ICC of each individual item was 0.913--0.968 (*P* \< 0.01); and the ICC of the total score was 0.976 (*P* \< 0.01). The ICC for inter-rater reliability was 0.844--0.941 (*P* \< 0.01), and the total score ICC was 0.965 (*P* \< 0.01). A 95% confidence interval was used for all ICCs. ICC values less than 0.4 indicate poor reliability, and values greater than 0.75 indicate good reliability (Pan and Ni, 1999).
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Intraclass correlation coefficient (ICC) results of each item
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Internal consistency measured by Cronbach\'s alpha was 0.636--0.701 (*P* \< 0.01), indicating high reliability.

Discussion {#sec1-4}
==========

Rating scales are commonly used to evaluate the severity of disease and efficacy of treatment, especially in neurological diseases and dyskinesia (Hobart et al., 2001; Middleton, 2012; Giang et al., 2013). OMNP is a common type of dyskinesia that affects patients' quality of life (Kuo et al., 2010). However, due to the complex manifestations of OMNP, it is difficult to assess its severity. To date, no study or scale has examined this issue and no system or scale is available to evaluate the severity of OMNP in neurology and ophthalmology, or to document the progression and degree of recovery. Therefore, to address this clinical need, this study designed a measurement scale and evaluated its reliability and validity.

Content validity {#sec2-8}
----------------

In the present study, I-CVI and S-CVI were used to assess the content validity. After correcting the random consistency (Pc = 0.016, K^\*^ = 1), the results still indicate good content validity (I-CVI = 0.83--1 S-CVI/UA = 0.83 S-CVI/Ave = 0.966) according to previous studies (Davis, 1992; Waltz et al., 2005). Good content validity not only demonstrates the strong association between scale scores and OMNP, but also indicates that the score reflects the severity of OMNP in some respects. All five items measure the symptoms and signs of OMNP and are strongly associated with its pathophysiology (Brazis, 2009; Cornblath, 2014). The testing method generally follows the accepted method of neuro-ophthalmology examination (Danchaivijitr, 2004; Brazis, 2009; Prasad and Volpe, 2010; Galtrey et al., 2015). We made some corrections and modifications to the scale to make it suitable for daily practice. For the eye movement measure, we graded horizontal movement on five levels and vertical movement on four levels according to the horizontal and vertical palpebral fissure size in healthy subjects. The reference values of the computerized diplopia test were horizontal 2.55° and vertical 0.76° (Zhou et al., 2016, 2017). The horizontal value is about three times the vertical value, which is why we multiplied the vertical measure by three before grading.

Construct validity {#sec2-9}
------------------

Factor analysis is generally used to assess construct validity. In this study, two common factors were extracted and their total contribution was 85.2%, which is significant factor analysis (Nia et al., 2017; Oh and Kim, 2017). After matrix rotation, eye movement, palpebral fissure, pupil size, and light reflex loaded on factor 1 and maximum angle of diplopia at 1 meter loaded on factor 2. We concluded that factor one measures the signs of OMNP and factor 2 reflects the symptoms of OMNP. The extraction of these two factors demonstrates that all five items reflect the symptoms and signs of OMNP. All items had loadings above 0.8 on their own factor, indicating agreement with the intended theoretical design of the scoring and confirming that the scale has good construct validity.

Reliability {#sec2-10}
-----------

The ICCs of inter-rater reliability and test-retest reliability were all above 0.75 (*P* \< 0.01), indicating very good reliability (Pan and Ni, 1999). The inter-rater and test-retest reliability results are similar to those of other scale development studies (Ardali et al., 2017; Cavalini et al., 2017; De Roo et al., 2017). Cronbach\'s alpha values were in the acceptable range, from 0.636--0.701 (*P* \< 0.01). Overall, the OMNPS shows good reliability. We excluded patients' scores for the angle of diplopia from the reliability and test-retest analysis; it would be meaningless for the patients to repeat the computerized diplopia test three times a day, because the data were automatically generated by computer and the error was very small.

The OMNPS includes three sub-scales for different types of OMNP (Newman and Bruce, 2007; Cornblath, 2014). For instance, abducens nerve paralysis only involves eye movement disorder and diplopia, and the other three items are irrelevant for these patients. Hence, we developed three sub-scales for different situations. PART CN-IV is scored from 0--4, PART CN-VI 0--8, and PART CN-III 0--27; higher scores indicate greater severity.

Bias {#sec2-11}
----

To minimize bias, we used various control processes (Kottner et al., 2011). The test order was randomized, and the tests were conducted in the consulting room and resembled the daily situation as far as possible. Communication between physicians was forbidden during the process (Stochkendahl et al., 2006). To avoid the Hawthorne effect, physicians who were not involved in the research compared the results (Wickstrom and Bendix, 2000). The single blind method was used for the physicians (Kottner et al., 2009). The data were cross-checked and consolidated by two other researchers.

Limitations {#sec2-12}
-----------

We did not report criterion validity, because there was no suitable standard method for comparison. The scale\'s application is limited to patients with unilateral mononeuropathy, because three items compare the affected eye with the healthy eye. The scale requires further modification to enable a wide range of application in the clinic. Rotation diplopia could not be quantified because the computerized diplopia test was based on the Hess principle. The Hess test does not assess rotation diplopia, but we believe that computerized diplopia testing will undergo further development. The sensitivity and responsiveness of the scale need to be investigated in the future.

Conclusion {#sec1-5}
==========

The OMNPS shows high content validity, construct validity, inter-rater reliability, test-retest reliability, and internal consistency. It is therefore suitable for use as a clinical scale to evaluate the severity of OMNP.
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